Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
about
Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.Patient considerations in the treatment of COPD: focus on the new combination inhaler fluticasone furoate/umeclidinium/vilanterol.
P2860
Once-Daily Triple Therapy in Patients with Advanced COPD: Healthcare Resource Utilization Data and Associated Costs from the FULFIL Trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Once-Daily Triple Therapy in P ...... d Costs from the FULFIL Trial.
@en
type
label
Once-Daily Triple Therapy in P ...... d Costs from the FULFIL Trial.
@en
prefLabel
Once-Daily Triple Therapy in P ...... d Costs from the FULFIL Trial.
@en
P2093
P2860
P1433
P1476
Once-Daily Triple Therapy in P ...... d Costs from the FULFIL Trial.
@en
P2093
Afisi S Ismaila
Chang-Qing Zhu
Dhvani Shah
Maggie Tabberer
Nancy A Risebrough
Noushin Brealey
Shiyuan Zhang
P2860
P2888
P304
P356
10.1007/S12325-017-0604-X
P407
P577
2017-09-05T00:00:00Z
P6179
1091493054